BeyondSpring Inc. (BYSI) Stock Analysis

Company Overview

BeyondSpring Inc. operates as a clinical stage biopharmaceutical entity dedicated to the development of cancer therapies through its specialized pipeline. The company functions within the Healthcare sector, specifically the Biotechnology industry, which implies a focus on high-risk, high-reward research and development aimed at advancing oncology treatments. BeyondSpring Inc. holds a market capitalization of $65.80M, reports no available annual revenue figures, and has an unlisted employee count. The company's market cap indicates a small-cap status typical for clinical-stage biotechs where value is derived entirely from potential asset approval rather than current cash flow, while the lack of reported revenue reflects a business model where expenses are incurred before product commercialization begins.

Financial Health

The company reports a net income of $-8,473,000 and an EBITDA of $-8,621,000, while annual revenue and free cash flow figures are not available. The substantial gap between the non-existent revenue and the significant negative net income reveals a cost structure dominated by research and development expenditures required to advance the Plinabulin pipeline through clinical trials. Operating margins, gross margins, and profit margins are all recorded at 0.0%, indicating that the company is not yet profitable and has not generated enough revenue to cover its operating costs. BeyondSpring Inc. maintains $12.56M in cash reserves against a total debt obligation of $320,000, suggesting a highly conservative balance sheet with minimal leverage. Although the debt-to-equity ratio is not available, the disparity between cash and debt implies the company has ample liquidity to fund its operations without immediate refinancing needs. The current ratio stands at 1.54, which indicates that the company possesses sufficient current assets to cover its short-term liabilities with a comfortable margin of safety. Return on Equity and Return on Assets are not available for calculation due to the lack of profit, though the Return on Assets is listed as -18.6%, signaling that asset deployment has resulted in a net loss position rather than a return on capital.

Valuation Assessment

The trailing twelve-month P/E ratio is not available, while the forward P/E is listed as -3.40, implying that the company is not currently profitable and future earnings estimates are either negative or undefined in standard multiples. The price-to-book ratio is -2.05, a negative figure that indicates the market values the company's equity at less than its book value, a common characteristic for biotech firms with intangible assets that have not yet been monetized. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also not available or negative at -7.16, reflecting the absence of positive earnings or sales needed for traditional valuation models. BeyondSpring Inc. trades between a 52-week high of $3.44 and a 52-week low of $0.98, with the current price sitting at a specific point within this historical range determined by market sentiment regarding its clinical progress. The beta value is not available, meaning there is no quantifiable data to describe the stock's volatility relative to the broader market index.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both not available due to the lack of historical positive financial data. Consequently, it is impossible to determine if earnings are growing faster or slower than revenue because both metrics are currently negative or non-existent in the reporting period. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This structure confirms that BeyondSpring Inc. reinvests all available resources, including its $12.56M cash balance, directly into its Plinabulin and TPD platform research rather than distributing income to shareholders. The overall growth and income profile for BeyondSpring Inc. is defined entirely by its potential for future clinical milestones rather than current cash generation or dividend income.